Cost Plus Drug Co. adds J&J's Janssen medications to its offerings, increasing affordability for diabetes patients.
Mark Cuban's Cost Plus Drug Co. has expanded its offerings to include brand-name medications from J&J subsidiary Janssen. The online wholesaler now sells three Janssen products, Invokana, Invokamet, and Invokamet XR, at significantly reduced prices compared to market rates.
Invokana, a highly effective medication for Type 2 diabetes, typically comes with a hefty price tag of over $675, as stated on Cost Plus Drugs' website. However, with Cuban's enterprise entering the scene, one can now access this vital treatment for a significantly reduced cost of just $243.90.
"This arrangement with Mark Cuban Cost Plus Drug Company is another example of how we [at Janssen] are supporting patient access to needed medicines especially for cash paying patients who are uninsured, or who are underinsured because of cost-shifting by commercial payers." a Janssen spokesperson stated in an emailed statement to The Street. "We have long-standing, strong relationships with all stakeholders across the healthcare system, including with PBMs, that are integral to our efforts to help us maintain market access for our products.”
Reference: Mark Cuban Has Good News for People with Diabetes | April 9, 2023 | Luc Olinga, TheStreet
Reference: Cuban's pharmacy picks up J&J brand-name drugs | April 4, 2023 | Becker's Hospital Review
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.